Quantitative immunoassay for complexes of prostate-specific antigen with α2-macroglobulin

Clinical Chemistry

Volumn 42, Issue 4, 1996, Pages 545-550

  España, Francisco ^a   Sánchez Cuenca, Jaime ^a   Estellés, Amparo ^a   Gilabert, Juan ^a   Griffin, John H ^b   Heeb, Mary J ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ELISA; protein C inhibitor; semen; seminal fluid; 1 antichymotrypsin

Indexed keywords

ALPHA 2 MACROGLOBULIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; QUANTITATIVE DIAGNOSIS; SEMINAL PLASMA; SPERM;

EID: 0029930146     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.4.545     Document Type: Article

References (31)

1. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981;2:89-96.
2. Armbruster DA. Prostate specific antigen: biochemistry, analytical methods, and clinical application [Review]. Clin Chem 1993;39: 181-95.
3. Lundwall A, Lilja H. Molecular cloning of human prostate-specific antigen cDNA. FEBS Lett 1987;214:317-22.
4. Watt KW, Lee PJ, M'timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986;83:3166-70.
5. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickly E. Isolation, characterization and amino-acid sequence of γ-semino-protein, a glycoprotein from human seminal plasma. Eur J Biochem 1987;170:111-20.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76: 1899-903.
7. Akiyama K, Nakamura T, Iwanang S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 1987;225:168-72.
8. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
9. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostate cancer. J Urol 1987;138:1181-4.
10. Partin AW, Oesterling JE. The clinical usefulness of prostate-specific antigen: update 1994 [Review]. J Urol 1994;152:1358-68.
11. Oesterling JE. Prostate-specific antigen: its role in the diagnosis and staging of prostate cancer. Cancer 1995;75:1795-804.
12. McCormack RT, Wang TJ, Rittenhouse HG, Wolfert RL, Finlay JA, Lilja H, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729-44.
13. Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbit JA, York JP, et al. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience. Urology 1989;34:187-93.
14. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
15. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
16. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
17. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
18. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787-94.
19. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
20. España F, Gilabert J, Estellés A, Romeu A, Aznar J, Cabo A. Functionally active protein C inhibitor/plasminogen activator-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentration in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991;64:309-20.
21. España F, Sánchez-Cuenca J, Vera CD, Estellés A, Gilabert J. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 1993;122:711-9.
22. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.
23. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
24. 1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol. In press.
25. Vessella RL. Trends in immunoassays of prostate-specific antigen. Serum complexes and ultrasensitivity. Clin Chem 1993;39: 2035-9.
26. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate-specific antigen. J Urol 1990;144:1523-6.
27. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-63.
28. España F, Griffin JH. Determination of functional and antigen protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. Thromb Res 1989;55:671-82.
29. España F, Hendl S, Gilabert J, Estellés A, Aznar J. Evaluation of two functional assays for the measurement of protein C inhibitor/ plasminogen activator inhibitor-3 (PCI/PAI-3) activity. Thromb Res 1993;70:375-84.
30. 2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 1993;69:448-53.
31. Laurell M, Christensson A, Abrahamsson PA, Stenflo J, Lilja H. Protein C inhibitor in human body fluids. J Clin Invest 1992;89: 1094-101.